Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts rate Mineralys Therapeutics “Moderate Buy”: Five of eight analysts recommend buying the stock, while two rate it a hold and one a sell. The average 12-month price target is $48.80.
• MLYS shares have declined sharply, opening at $23.72 versus a 52-week high of $47.65; the company also reported a quarterly EPS loss of $2.85, missing the $0.55 loss estimate.
• Institutional ownership is substantial at 84.46%, with several funds adding positions, while insiders sold 133,974 shares worth approximately $3.8 million over the past 90 days.

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $48.80.

A number of research analysts have recently weighed in on the company. Zacks Research upgraded Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, September 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th.

Insider Activity at Mineralys Therapeutics

In related news, Director Daphne Karydas sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total transaction of $85,740.00. Following the completion of the sale, the director directly owned 6,200 shares in the company, valued at approximately $177,196. This trade represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 7,438 shares of the firm's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $28.12, for a total transaction of $209,156.56. Following the sale, the insider owned 38,400 shares of the company's stock, valued at approximately $1,079,808. This represents a 16.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 133,974 shares of company stock valued at $3,817,995 over the last ninety days. 18.94% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors have recently modified their holdings of MLYS. BlueCrest Capital Management Ltd purchased a new position in shares of Mineralys Therapeutics during the 2nd quarter valued at $2,298,000. WINTON GROUP Ltd purchased a new stake in shares of Mineralys Therapeutics during the second quarter worth $912,000. Arizona State Retirement System raised its holdings in shares of Mineralys Therapeutics by 22.4% during the second quarter. Arizona State Retirement System now owns 15,357 shares of the company's stock worth $414,000 after acquiring an additional 2,815 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Mineralys Therapeutics during the second quarter valued at $333,000. Finally, Pale Fire Capital SE boosted its position in Mineralys Therapeutics by 68.0% during the second quarter. Pale Fire Capital SE now owns 614,284 shares of the company's stock valued at $16,573,000 after purchasing an additional 248,658 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.

Mineralys Therapeutics Trading Down 5.6%

Mineralys Therapeutics stock opened at $23.72 on Friday. Mineralys Therapeutics has a 52 week low of $22.30 and a 52 week high of $47.65. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -5.59 and a beta of 0.69. The company has a 50 day moving average price of $26.95 and a 200 day moving average price of $27.02.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Research analysts forecast that Mineralys Therapeutics will post -4.45 EPS for the current year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular and kidney-related conditions associated with excess aldosterone activity. The company is headquartered in Radnor, Pennsylvania.

Mineralys' lead product candidate is lorundrostat, an oral, highly selective aldosterone synthase inhibitor designed to reduce the production of aldosterone. The company is evaluating lorundrostat as a potential treatment for uncontrolled or resistant hypertension, including hypertension linked to abnormal activation of the renin-angiotensin-aldosterone system.

Mineralys was established to advance therapies targeting aldosterone-driven disease and became a publicly traded company on the Nasdaq exchange in 2023.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.